CytomX Therapeutics
CTMX
69 hedge funds and large institutions have $60.4M invested in CytomX Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 13 closing their positions.
1,330% more call options, than puts
Call options by funds: $143K | Put options by funds: $10K
0.48% more ownership
Funds ownership: 65.05% → 65.53% (+0.48%)
2% less capital invested
Capital invested by funds: $61.9M → $60.4M (-$1.44M)
7% less funds holding
Funds holding: 74 → 69 (-5)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$3.84M |
| 2 |
ACM
Altium Capital Management
New York
|
+$1.16M |
| 3 |
Millennium Management
New York
|
+$908K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$515K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$500K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$1.9M |
| 2 |
RI
RTW Investments
New York
|
-$1.46M |
| 3 |
SCM
Superstring Capital Management
New York
|
-$1.4M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$366K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$353K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Two Sigma Advisers
New York
| – | -$193K | -158,400 | Closed |
|
|
LP
77
LMR Partners
London,
United Kingdom
| – | -$18.4K | -15,046 | Closed |
|
78
Simplex Trading
Chicago,
Illinois
| – | -$4.94K | -3,891 | Closed |
|
|
WT
79
Whittier Trust
South Pasadena,
California
| – | -$2.68K | -2,200 | Closed |
|
80
RhumbLine Advisers
Boston,
Massachusetts
| – | -$1.57K | -1,291 | Closed |
|
|
IC
81
Innealta Capital
Austin,
Texas
| – | -$2 | -2 | Closed |
|
CTMX Hedge Fund Activity: Q3 2024 in Review
69 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2024, worth a combined $60.4M — down 2.3% from $61.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CTMX and 9 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was Prosight Management, opening a new position worth an estimated $3.84M. The largest seller was Janus Henderson Group, cutting an estimated $1.9M.
- 69 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2024, down from 74 in Q2 2024.
- Funds reported $60.4M of CytomX Therapeutics stock for Q3 2024, down 2.3% quarter-over-quarter.
- 9 funds opened new CytomX Therapeutics positions in Q3 2024 and 13 closed out, a net change of -4 holders.
- The largest CytomX Therapeutics buyer in Q3 2024 was Prosight Management, an estimated $3.84M added.
- The largest CytomX Therapeutics seller in Q3 2024 was Janus Henderson Group, an estimated $1.9M sold.
Based on aggregated 13F filings for Q3 2024.